In this video from Motley Fool Live, recorded on Feb. 1, Fool.com contributors Brian Orelli and Keith Speights discuss the implications of President Joe Biden’s administration buying an additional 200 million doses of coronavirus vaccines, split between Moderna (NASDAQ: MRNA) and the duo of Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX). On Feb. 11, Biden announced that deals had been finalized with the companies, although critical details of pricing were left out. The additional doses are expected to be delivered by the end of July.
Can COVID Vaccine Makers Benefit From the Biden Administration?
Latest from Blog
Moderna (NASDAQ: MRNA) has been among the first to address the biggest challenge facing coronavirus vaccines…
Whether you’re nearing retirement or already there, you want low-volatility investments that generate income during your…
How long should you hold on to a winning stock? That question is an important one…
For three weeks shy of one year, investors have enjoyed one of the greatest bounce-back rallies…
The clock is ticking on the completion of the biggest marijuana merger ever. Aphria (NASDAQ: APHA)…